{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Lanoxin"},{"type":"Synonym","name":"12beta-hydroxydigitoxin"},{"type":"CASRegistryName","name":"20830-75-5"},{"type":"ChemicalStructureName","name":"3beta,12beta,14-trihydroxy-5beta,14beta-card-20(22)-enolid-3-tridigitoxosid"},{"type":"USBrandName","name":"Cardiogoxin"},{"type":"Synonym","name":"digoxigenin-tridigitoxosid"}],"definition":{"html":"A cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility. This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity. Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3.","text":"A cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility. This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity. Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3."},"drugInfoSummaryLink":null,"nciConceptId":"C28990","nciConceptName":"Digoxin","termId":485249,"name":"digoxin","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"digoxin"},{"aliases":[{"type":"CodeName","name":"CLS003"},{"type":"CodeName","name":"CLS 003"},{"type":"CodeName","name":"CLS-003"},{"type":"Synonym","name":"digoxin-furosemide topical gel CLS003"},{"type":"Synonym","name":"ICVT product CLS003"}],"definition":{"html":"A topical ionic contra-viral therapy (ICVT) gel-based formulation that combines furosemide, a sulfamoylanthranilic acid derivative and loop diuretic, and digoxin, a cardiac glycoside, with potential antiviral activity. Upon topical administration, furosemide interacts with the cell membrane ion co-transporter, Na+-K+-2Cl-co-transporter-1(NKCC1; SLC12A2) and digoxin reversibly inhibits the sodium/potassium-transporting ATPase, leading to a decrease in potassium influx. This may prevent the replication of certain DNA viruses including human papillomavirus (HPV), that rely on potassium for replication.","text":"A topical ionic contra-viral therapy (ICVT) gel-based formulation that combines furosemide, a sulfamoylanthranilic acid derivative and loop diuretic, and digoxin, a cardiac glycoside, with potential antiviral activity. Upon topical administration, furosemide interacts with the cell membrane ion co-transporter, Na+-K+-2Cl-co-transporter-1(NKCC1; SLC12A2) and digoxin reversibly inhibits the sodium/potassium-transporting ATPase, leading to a decrease in potassium influx. This may prevent the replication of certain DNA viruses including human papillomavirus (HPV), that rely on potassium for replication."},"drugInfoSummaryLink":null,"nciConceptId":"C162192","nciConceptName":"Furosemide/Digoxin Topical Gel CLS003","termId":798476,"name":"furosemide/digoxin topical gel CLS003","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"furosemide-digoxin-topical-gel-cls003"}],"links":null}